Ankush Paladhi

Ankush Paladhi

Auto-generated profile, based on publicly available information

Ankush Paladhi

Cellular Immunology Laboratory, Department of Zoology, The University of Burdwan, Burdwan, India

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
APAnkush Paladhi
Ankush Paladhi
SDSamrat Daripa
Samrat Daripa
IMIndrani Mondal
Indrani Mondal
SHSumit Kumar Hira
Sumit Kumar Hira
T-cell exhaustion plays a pivotal role in the resistance of microsatellite-stable colorectal cancer (CRC) to immunotherapy. Identifying and targeting T-cell exhaustion-activating mechanisms is a promising strategy to augment the effects of immunotherapy. Here, we found that thymidine phosphorylase (TYMP) plays a decisive role in inducing systemic T-cell exhaustion and abrogating the efficacy of dendritic cell (DC) therapy in a CRC model. Targeting TYMP with tipiracil hydrochloride (TPI) induces immunological cell death (ICD). The combined effects of TPI and imiquimod-activated DCs turn CT26 tumors into immunologically ‘hot’ tumors by inducing ICD in vivo. High-dimensional cytometry analysis revealed T-cell and IFN-γ dependency on the therapeutic outcome. In addition, chemoimmunotherapy converts intratumoral Treg cells into Th1 effector cells and eliminates tumor-associated macrophages, resulting in higher cytotoxic T lymphocyte infiltration and activation. This effect is also associated with the downregulation of PD-L1 expression in tumors, leading to the prevention of T-cell exhaustion. Thus, cooperative and cognitive interactions between dendritic cells and immunogenic cell death induced by therapy with TPI promote the immune response and tumoricidal activities against microsatellite stable colorectal cancer. Our results support TYMP targeting to improve the effects of DC immunotherapy and outcomes in CRC.

6 January 2020 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
PSPrateek Srivastava
Prateek Srivastava
SHSumit Kumar Hira
Sumit Kumar Hira
APAnkush Paladhi
Ankush Paladhi
RSRanjeet Singh
Ranjeet Singh
UGUttam Gupta
Uttam Gupta
PMPartha Pratim Manna
Partha Pratim Manna
A triple stimuli-responsive drug delivery platform involving doxorubicin, 5-fluoro-2-deoxy uridine and folic acid was fabricated on mesoporous silica nanoparticles for targeting delivery against a highly aggressive murine lymphoma called Dalton's lymphoma. Fabrication of the unique construct by amalgamating active and passive targeting mechanisms offers a novel hyper-chimeric platform for a stimuli-responsive drug delivery system. The novel construct enables efficient and precise delivery of the precious cargo to the tumor sites. Active targeting by folic acid directs the doxorubicin and 5-fluoro-2-deoxy uridine in the close proximities of the tumor cells, causing efficient killing and significant growth inhibition. Isobologram models, zero interaction potency dose–response surface plots and matrices were generated to evaluate the combination synergism of the two drugs. Therapy with the dual drug-bearing construct in mice with established tumors significantly reduced the tumor load and enhanced the survival of the animals compared with the untreated control. Therapy with the dual delivery system also augmented the innate and adaptive immune defense mechanisms of the treated animals. CD8+ T cells, natural killer cells and the dendritic cells from the treated group following successful therapy with the novel construct showed enhanced cytotoxicity and growth inhibitory capacities against DL tumor cells.

1 April 2019 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
MKMohammad Kashif
Mohammad Kashif
SHSumit Kumar Hira
Sumit Kumar Hira
AUAnurag Upadhyaya
Anurag Upadhyaya
UGUttam Gupta
Uttam Gupta
RSRanjeet Singh
Ranjeet Singh
PMPartha Pratim Manna
Partha Pratim Manna

1 January 2020 in International Immunopharmacology
Verified
Journal Article
Closed access
UGUttam Gupta
Uttam Gupta
SHSumit Kumar Hira
Sumit Kumar Hira
RSRanjeet Singh
Ranjeet Singh
APAnkush Paladhi
Ankush Paladhi
PSPrateek Srivastava
Prateek Srivastava
PMPartha Pratim Manna
Partha Pratim Manna

23 June 2020 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
MKMohammad Kashif
Mohammad Kashif
APAnkush Paladhi
Ankush Paladhi
RSRanjeet Singh
Ranjeet Singh
SBSankar Bhattacharyya
Sankar Bhattacharyya
SHSumit Kumar Hira
Sumit Kumar Hira
PMPartha Pratim Manna
Partha Pratim Manna
Peroxidases are a heterogeneous family of enzymes that have diverse biological functions. Ascorbate peroxidase is a redox enzyme that is reduced by trypanothione, which plays a central role in the redox defense system of Leishmania . In view of developing new and novel therapeutics, we performed in silico studies in order to search for a ligand library and identify new drug candidates and their physiological roles against promastigotes and intracellular amastigotes of Leishmania donovani .

6 September 2024 in The Journal of Immunology
Verified
Journal Article
Closed access
APAnkush Paladhi
Ankush Paladhi
SDSamrat Daripa
Samrat Daripa
ANArghya Nath
Arghya Nath
SHSumit Kumar Hira
Sumit Kumar Hira
Dendritic cell (DC)–based vaccines are promising immunotherapies for cancer. Although DC-based therapies are known to activate tumor-specific T cells, the interplay between DCs and NK cells in this setting is not fully understood. In this study, we demonstrated a novel TLR7/ mitochondrial reactive oxygen species (mROS)/IL-12 axis that drives potent NK cell responses against tumors. We showed that TLR7 activation by imiquimod in peripheral blood monocyte-derived CD11c+ DCs triggered mROS production, leading to enhanced IL-12 secretion and subsequent NK cell activation, as evidenced by increased IFN-γ production and tumor cell cytotoxicity. Notably, mROS neutralization abrogates NK cell–mediated tumor cell lysis, and TLR7-mediated DC activation of NK cells occurs independently of MyD88, suggesting involvement of the noncanonical NF-κB pathway. Our findings provide a rationale for targeting the TLR7/mROS/IL-12 axis to enhance the efficacy of DC-based cancer immunotherapy.